Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment

Figures & data

Table 1 Demographic and Baseline Clinical Features of Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment

Feature	Number
Age (yrs), mean±SD (range)	60.2 ± 7.2 (49–71)
Sex, n (%)
Male	10 (58.8)
Female	7 (41.2)
Hypertension, n (%)	13 (76.5)
Anti-VEGF therapy, n (%)
Ranibizumab	9 (52.9)
Conbercept	7 (41.2)
Aflibercept	1 (5.9)
Injections before being LTFU, mean±SD (range)	4.5 ± 1.5 (2–8)
Treatment length before being LTFU (months), mean±SD (range)	6.1 ± 3.3 (2–14)

Abbreviation: VEGF, vascular endothelial growth factor.

Table 2 Treatment Interruption and Resulting Complications in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment

Feature	Number
BCVA before being LTFU (logMAR), mean±SD	0.59 ± 0.18
CRT before being LTFU (μm), mean±SD	360.9 ± 87.6
Reason for being LTFU, n (%)
Noncomliance	6 (35)
Financial issues	5 (29)
Intercurrent illness	4 (24)
Other	2 (12)
LTFU length (months), mean±SD (median)	7.8 ± 2.1 (7.0)
BCVA on return visit (logMAR), mean±SD	1.54 ± 0.61
CRT on return visit (μm), mean±SD	738.7 ± 143.6
Complication on return visit, n (%)
ME worsening	13 (76.5)
Vitreous hemorrhage	4 (23.5)
NVD or NVE	3 (17.6)
Neovascular glaucoma	1 (5.9)
Follow-up length from return to final visit (months), mean±SD (range)	8.5 ± 2.5 (6–13)
BCVA at final visit (logMAR), mean±SD	1.26 ± 0.57
CRT at final visit (μm), mean±SD	469.9 ± 302.9

Note: CRT on return visit available for 13 eyes without vitreous hemorrhage.

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; LogMAR, logarithm of minimal angle of resolution; SD, standard deviation; LTFU, lost to follow-up; ME, macular edema; NVD, neovascularization of the disc; NVE, neovascularization elsewhere.

Table 3 Comparison of Clinical Features in Patients without or with Neovascular Complications

Feature	Non Neovascualr Complications n=10	Neovascular Complications n=7	P value
Age (yrs), mean±SD (range)	58.8 ± 5.3 (53–67)	62.3 ± 9.3 (49–71)	0.364
Sex, n (%)			0.350
Male	7 (60)	3 (57.1)
Female	3 (40)	4 (42.9)
Hypertension, n (%)	7 (80)	6 (71.4)	0.603
Injections before being LTFU, mean±SD (range)	4.1 ± 1.4 (2–7)	5.0 ± 1.6 (3–8)	0.270
Treatment length before being LTFU (months), mean±SD (range)	5.2 ± 3.0 (2–12)	7.4 ± 3.6 (3–14)	0.161
BCVA before being LTFU (logMAR), mean±SD	0.56 ± 0.20	0.64 ± 0.15	0.364
CRT before being LTFU (μm), mean±SD	348.1 ± 103.6	379.3 ± 60.7	0.193
LTFU length (months), mean±SD (median)	6.7 ± 0.8 (6.3)	9.3 ± 2.4 (9)	0.007*
BCVA on return visit (logMAR), mean±SD	1.14 ± 0.33	2.11 ± 0.41	0.001*
Follow-up length from return to final visit (months), mean±SD (range)	7.7 ± 2.1 (6–12)	9.6 ± 2.8 (6–13)	0.161
BCVA at final visit (logMAR), mean±SD	1.05 ± 0.35	1.56 ± 0.72	0.070
CRT at final visit (μm), mean±SD	530.6 ± 307.5	383.3 ± 296.5	0.550

Note: *Indicates statistically significant P value.

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; LogMAR, logarithm of minimal angle of resolution; SD, standard deviation; LTFU, lost to follow-up.

Table 4 Association Between Baseline Characteristics and Best-Corrected Visual Acuity at Final Visit After Treatment Discontinuation

Baseline Characteristics	P value	β	95% Confidence Intervals
Age (yrs)	0.940
Sex, male: female	0.464
Hypertension	0.594
Number of injections before being LTFU	0.240
Treatment length before being LTFU (months)	0.158
BCVA before being LTFU (logMAR)	0.548
CRT before being LTFU (μm)	0.169
LTFU length (months)	<0.001	0.917	0.191–0.312

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; LogMAR, logarithm of minimal angle of resolution; LTFU, lost to follow-up.